Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Dar Bioscience Inc's Business Segments
Dar Bioscience Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable99.7%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 0 | 99.7% |
Revenue by Product & Service Category - Q1 FY2026
- Royalty99.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 99.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Dar Bioscience Inc
Dar Bioscience Inc., also known as Daré Bioscience, is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company is focused on developing and commercializing innovative products for women's reproductive health. Daré Bioscience was founded in 2015 and became a public company in 201
The company is led by CEO Sabrina Martucci Johnson, who has more than 20 years of experience in healthcare and biopharmaceutical industries. Johnson is supported by a team of experienced professionals, including researchers, clinical trial specialists, business leaders, and medical doctors.
Daré Bioscience is developing a portfolio of product candidates designed to address unmet needs in women's reproductive health, including contraception, fertility, and menopause. The company's lead product candidate is Ovaprene, a hormone-free, monthly contraceptive ring designed to prevent pregnancy for up to three months. Ovaprene is currently in Phase 2 clinical trials and has the potential to provide women with a noninvasive and discrete contraceptive option.
In addition to Ovaprene, Daré Bioscience is also developing other innovative product candidates, including:
- Sildenafil Cream, a topical treatment for female sexual arousal disorder that is currently in Phase 3 clinical trials
- D-Ovulation, a handheld, battery-operated device that tracks ovulation by measuring hormone levels that is currently in Phase 2 clinical trials
- Vaginal tamoxifen, a treatment for vaginal dryness in women with breast cancer that is currently in Phase 1 clinical trials
Daré Bioscience has a strong intellectual property portfolio that includes multiple patents and patent applications covering its product candidates and technology platforms. The company is also actively pursuing strategic partnerships and collaborations with other companies and organizations to advance its product candidates and bring them to market.
Overall, Daré Bioscience is a dynamic and innovative biopharmaceutical company that is dedicated to improving women's reproductive health through the development of safe and effective products. With a strong pipeline of product candidates and a committed team of professionals, the company is well positioned to address unmet needs in this important area of healthcare.
The company is led by CEO Sabrina Martucci Johnson, who has more than 20 years of experience in healthcare and biopharmaceutical industries. Johnson is supported by a team of experienced professionals, including researchers, clinical trial specialists, business leaders, and medical doctors.
Daré Bioscience is developing a portfolio of product candidates designed to address unmet needs in women's reproductive health, including contraception, fertility, and menopause. The company's lead product candidate is Ovaprene, a hormone-free, monthly contraceptive ring designed to prevent pregnancy for up to three months. Ovaprene is currently in Phase 2 clinical trials and has the potential to provide women with a noninvasive and discrete contraceptive option.
In addition to Ovaprene, Daré Bioscience is also developing other innovative product candidates, including:
- Sildenafil Cream, a topical treatment for female sexual arousal disorder that is currently in Phase 3 clinical trials
- D-Ovulation, a handheld, battery-operated device that tracks ovulation by measuring hormone levels that is currently in Phase 2 clinical trials
- Vaginal tamoxifen, a treatment for vaginal dryness in women with breast cancer that is currently in Phase 1 clinical trials
Daré Bioscience has a strong intellectual property portfolio that includes multiple patents and patent applications covering its product candidates and technology platforms. The company is also actively pursuing strategic partnerships and collaborations with other companies and organizations to advance its product candidates and bring them to market.
Overall, Daré Bioscience is a dynamic and innovative biopharmaceutical company that is dedicated to improving women's reproductive health through the development of safe and effective products. With a strong pipeline of product candidates and a committed team of professionals, the company is well positioned to address unmet needs in this important area of healthcare.
Dare Bioscience Inc. Overview
Dare Bioscience Inc. is a biopharmaceutical company committed to the development and commercialization of innovative products specifically for womens health. The company operates across various segments targeting significant unmet medical needs, with a focus on reproductive health and oncology. Its product offerings span a range of therapeutic areas, highlighting an unwavering dedication to improving women’s health outcomes.
Segments
1. Reproductive Health
- This segment serves as Dare Bioscience’s core focus, addressing critical health issues faced by women, particularly those pertinent to the reproductive system. Products in this segment aim to meet the demands for better treatment alternatives in areas such as bacterial vaginosis, menstrual irregularities, and infertility issues.
- Key Product: DARE-BV1, a gel-based therapy for bacterial vaginosis, exemplifies the innovation in this segment, alongside various emerging products aimed at menstrual cycle regulation and fertility enhancement.
2. Oncology
- The oncology segment concentrates on developing specialized products that address cancer conditions predominantly affecting women, such as breast and ovarian cancer. Through this segment, Dare Bioscience aims to contribute to the advancement of treatments that can significantly improve survival rates and quality of life for female cancer patients.
Products
1. DARE-BV1
- Overview: A microbiome-based, bioadhesive gel specifically formulated to treat bacterial vaginosis.
- Development Stage: Currently in late-stage clinical trials, DARE-BV1 has shown promising efficacy in clinical studies, positioning it as a potential first-line treatment option for this common gynecological condition.
2. DARE-HRT1
- Overview: Developed to cater to unmet needs in hormone replacement therapy, this product aims to alleviate menopausal symptoms such as hot flashes and mood swings.
- Development Stage: Currently in preclinical development, DARE-HRT1 seeks to provide effective symptom relief without systemic side effects typically associated with conventional hormone therapies.
3. DARE-FRT1
- Overview: Aimed at regulating fertility, this product is designed to enhance reproductive wellness among women and address hormonal fluctuations during the menopausal transition.
- Unique Benefit: It aims not only to stabilize hormonal balance but also to improve related symptoms, such as mood and libido, thereby enhancing overall wellbeing.
4. DARE-SA1
- Overview: Focused on treating vulvar and vaginal atrophy, this product is designed to provide relief from vaginal dryness and discomfort during sexual intercourse, which are common issues faced by menopausal women.
- Expected Outcome: By improving vaginal lubrication and reducing discomfort, DARE-SA1 aims to help restore quality of life and intimacy for women experiencing menopausal symptoms.
Services
1. Clinical Research and Development
- Dare Bioscience engages in rigorous clinical trials to assess the safety and efficacy of its products, demonstrating a commitment to scientific excellence and regulatory compliance in product development.
- A robust pipeline reflects the company’s focus on innovative solutions tailored to womens health needs.
2. Manufacturing
- The company partners with experienced contract manufacturers to ensure the production of high-quality, compliant products that meet stringent industry standards, reinforcing its pledge to quality.
3. Regulatory Affairs
- Dare Bioscience is dedicated to navigating the complex regulatory landscape to ensure all products meet necessary safety standards and regulatory requirements. The company collaborates closely with regulatory agencies to facilitate smooth approval processes for its products.
4. Marketing and Sales
- Utilizing a multichannel marketing approach, Dare Bioscience promotes its products through direct-to-consumer advertising networks and strategic partnerships with healthcare professionals and medical institutions.
- This comprehensive strategy ensures that products reach the women who need them most, bridging gaps in awareness and access in womens health.
In summary, Dare Bioscience Inc. strives to make impactful contributions to women’s health through its dedicated segments, innovative products, and robust services, focusing on addressing significant health challenges faced by women today.
Dare Bioscience Inc. is a biopharmaceutical company committed to the development and commercialization of innovative products specifically for womens health. The company operates across various segments targeting significant unmet medical needs, with a focus on reproductive health and oncology. Its product offerings span a range of therapeutic areas, highlighting an unwavering dedication to improving women’s health outcomes.
Segments
1. Reproductive Health
- This segment serves as Dare Bioscience’s core focus, addressing critical health issues faced by women, particularly those pertinent to the reproductive system. Products in this segment aim to meet the demands for better treatment alternatives in areas such as bacterial vaginosis, menstrual irregularities, and infertility issues.
- Key Product: DARE-BV1, a gel-based therapy for bacterial vaginosis, exemplifies the innovation in this segment, alongside various emerging products aimed at menstrual cycle regulation and fertility enhancement.
2. Oncology
- The oncology segment concentrates on developing specialized products that address cancer conditions predominantly affecting women, such as breast and ovarian cancer. Through this segment, Dare Bioscience aims to contribute to the advancement of treatments that can significantly improve survival rates and quality of life for female cancer patients.
Products
1. DARE-BV1
- Overview: A microbiome-based, bioadhesive gel specifically formulated to treat bacterial vaginosis.
- Development Stage: Currently in late-stage clinical trials, DARE-BV1 has shown promising efficacy in clinical studies, positioning it as a potential first-line treatment option for this common gynecological condition.
2. DARE-HRT1
- Overview: Developed to cater to unmet needs in hormone replacement therapy, this product aims to alleviate menopausal symptoms such as hot flashes and mood swings.
- Development Stage: Currently in preclinical development, DARE-HRT1 seeks to provide effective symptom relief without systemic side effects typically associated with conventional hormone therapies.
3. DARE-FRT1
- Overview: Aimed at regulating fertility, this product is designed to enhance reproductive wellness among women and address hormonal fluctuations during the menopausal transition.
- Unique Benefit: It aims not only to stabilize hormonal balance but also to improve related symptoms, such as mood and libido, thereby enhancing overall wellbeing.
4. DARE-SA1
- Overview: Focused on treating vulvar and vaginal atrophy, this product is designed to provide relief from vaginal dryness and discomfort during sexual intercourse, which are common issues faced by menopausal women.
- Expected Outcome: By improving vaginal lubrication and reducing discomfort, DARE-SA1 aims to help restore quality of life and intimacy for women experiencing menopausal symptoms.
Services
1. Clinical Research and Development
- Dare Bioscience engages in rigorous clinical trials to assess the safety and efficacy of its products, demonstrating a commitment to scientific excellence and regulatory compliance in product development.
- A robust pipeline reflects the company’s focus on innovative solutions tailored to womens health needs.
2. Manufacturing
- The company partners with experienced contract manufacturers to ensure the production of high-quality, compliant products that meet stringent industry standards, reinforcing its pledge to quality.
3. Regulatory Affairs
- Dare Bioscience is dedicated to navigating the complex regulatory landscape to ensure all products meet necessary safety standards and regulatory requirements. The company collaborates closely with regulatory agencies to facilitate smooth approval processes for its products.
4. Marketing and Sales
- Utilizing a multichannel marketing approach, Dare Bioscience promotes its products through direct-to-consumer advertising networks and strategic partnerships with healthcare professionals and medical institutions.
- This comprehensive strategy ensures that products reach the women who need them most, bridging gaps in awareness and access in womens health.
In summary, Dare Bioscience Inc. strives to make impactful contributions to women’s health through its dedicated segments, innovative products, and robust services, focusing on addressing significant health challenges faced by women today.